Germany's BioNTech to buy CureVac to boost cancer research / Photo: ANDRE PAIN - AFP
RBGPF
0.1000
Dubai Telegraph - Germany's BioNTech to buy CureVac to boost cancer research
EUR
-
AED 4.333945
AFN 77.887151
ALL 96.474738
AMD 446.387728
ANG 2.112487
AOA 1082.158989
ARS 1708.501219
AUD 1.686989
AWG 2.125669
AZN 2.010175
BAM 1.953256
BBD 2.375636
BDT 144.132249
BGN 1.981838
BHD 0.444912
BIF 3493.118957
BMD 1.180108
BND 1.500545
BOB 8.150418
BRL 6.183168
BSD 1.179479
BTN 106.74341
BWP 15.532832
BYN 3.368212
BYR 23130.11201
BZD 2.37218
CAD 1.612777
CDF 2625.73975
CHF 0.917268
CLF 0.025649
CLP 1012.780302
CNY 8.187825
CNH 8.189275
COP 4282.1154
CRC 584.718509
CUC 1.180108
CUP 31.272856
CVE 110.116893
CZK 24.372651
DJF 209.729075
DKK 7.467836
DOP 73.993927
DZD 153.079662
EGP 55.345637
ERN 17.701616
ETB 182.736137
FJD 2.602315
FKP 0.86138
GBP 0.864819
GEL 3.180373
GGP 0.86138
GHS 12.951184
GIP 0.86138
GMD 86.147641
GNF 10351.077805
GTQ 9.046909
GYD 246.769596
HKD 9.219178
HNL 31.162539
HRK 7.535581
HTG 154.599269
HUF 379.63596
IDR 19834.071049
ILS 3.652203
IMP 0.86138
INR 106.731129
IQD 1545.19373
IRR 49712.039391
ISK 144.796826
JEP 0.86138
JMD 184.959067
JOD 0.836717
JPY 185.210858
KES 152.175039
KGS 103.200068
KHR 4760.818583
KMF 493.285381
KPW 1062.032235
KRW 1723.806746
KWD 0.362683
KYD 0.982924
KZT 585.944944
LAK 25371.05838
LBP 105624.757488
LKR 365.052098
LRD 219.384223
LSL 18.850106
LTL 3.484551
LVL 0.713835
LYD 7.453974
MAD 10.812948
MDL 19.957088
MGA 5225.215613
MKD 61.616688
MMK 2478.150907
MNT 4212.803755
MOP 9.491776
MRU 46.835403
MUR 54.143869
MVR 18.232624
MWK 2044.881053
MXN 20.447408
MYR 4.639592
MZN 75.231987
NAD 18.850824
NGN 1615.048331
NIO 43.403829
NOK 11.419029
NPR 170.820208
NZD 1.967092
OMR 0.453702
PAB 1.179469
PEN 3.965035
PGK 5.053246
PHP 69.568537
PKR 329.895286
PLN 4.218
PYG 7806.566323
QAR 4.30205
RON 5.094998
RSD 117.391206
RUB 89.984704
RWF 1721.464861
SAR 4.425427
SBD 9.509428
SCR 16.184535
SDG 709.834768
SEK 10.608431
SGD 1.502163
SHP 0.885386
SLE 28.883122
SLL 24746.268716
SOS 672.926277
SRD 44.719019
STD 24425.847913
STN 24.468438
SVC 10.320119
SYP 13051.490107
SZL 18.849526
THB 37.45618
TJS 11.022488
TMT 4.142178
TND 3.411341
TOP 2.841416
TRY 51.369267
TTD 7.989795
TWD 37.376496
TZS 3045.020483
UAH 50.882013
UGX 4199.529565
USD 1.180108
UYU 45.458858
UZS 14458.675608
VES 438.575913
VND 30661.559706
VUV 141.089893
WST 3.217174
XAF 655.106414
XAG 0.013133
XAU 0.000235
XCD 3.189301
XCG 2.12574
XDR 0.813661
XOF 655.120274
XPF 119.331742
YER 281.308183
ZAR 18.976192
ZMK 10622.385043
ZMW 23.089021
ZWL 379.994216
- AI to track icebergs adrift at sea in boon for science
- Indigenous Brazilians protest Amazon river dredging for grain exports
- Google's annual revenue tops $400 bn for first time, AI investments rise
- Man City brush aside Newcastle to reach League Cup final
- Guardiola wants permission for Guehi to play in League Cup final
- Boxer Khelif reveals 'hormone treatments' before Paris Olympics
- BHP damages trial over Brazil mine disaster to open in 2027
- Dallas deals Davis to Wizards in blockbuster NBA trade: report
- Lens cruise into French Cup quarters, Endrick sends Lyon through
- No.1 Scheffler excited for Koepka return from LIV Golf
Germany's BioNTech to buy CureVac to boost cancer research
Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.
BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".
Both biotech companies have been working for years in the area of mRNA vaccines and treatments, which provoke an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells.
While the technology became well known in relation to some Covid-19 vaccines, it is also being used in other areas, and scientists believe it could be a game-changer against many diseases.
BioNTech said the acquisition of CureVac would help boost its work in the field of mRNA-based cancer immunotherapy -- treatment that uses the body's own immune system to fight diseases.
"This transaction is another building block in BioNTech's oncology strategy and an investment in the future of cancer medicine," said BioNTech CEO Ugur Sahin.
It was aimed at "establishing new standards of care for various types of cancer in the coming years," he said.
Alexander Zehnder, CEO of CureVac, said the purchase would bring scientific expertise, technology and manufacturing know-how "in the mRNA field under one roof".
BioNTech's all-stock acquisition has been unanimously approved by the companies' management and supervisory boards, and is expected to close in 2025, subject to certain conditions including regulatory approvals.
Both companies are listed on the Nasdaq Composite Index.
They had both sought to develop Covid-19 vaccines during the pandemic, with Mainz-based BioNTech's Comirnaty jab winning approval and going on to become one of the most widely used shots against the virus around the world.
But Tuebingen-based CureVac, founded 25 years ago by mRNA pioneer Ingmar Hoerr, abandoned its efforts in late 2021 after disappointing trial results.
In 2022, CureVac sued BioNTech for patent infringement over its rival's use of the technology.
G.Gopalakrishnan--DT
